drugset / Trial / NCT06713317
A Phase I Study to Evaluate the Safety and Drug Allergy of HLB3-002 in Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
Part I) multi-center, randomized, double-blind, placebo controlled Part II) multi-center, randomized, double-blind, placebo controlled
Timeline
- Start
- 2024-12-02
- Primary completion
- 2025-06-27
- Completion
- 2025-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLB3-002 | Unknown | — | — |
Indications
No indication recorded.